|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression multiple interactions |
ISO |
Ursolic Acid results in decreased expression of ABCB1 mRNA; Ursolic Acid results in decreased expression of ABCB1 protein ABCB1 protein inhibits the reaction [Ursolic Acid results in increased susceptibility to Doxorubicin] |
CTD |
PMID:33009882 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
Ursolic Acid results in increased phosphorylation of ACACA protein |
CTD |
PMID:24802810 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of ACKR3 mRNA; Ursolic Acid results in decreased expression of ACKR3 protein |
CTD |
PMID:35786050 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression affects expression |
ISO |
Ursolic Acid results in decreased expression of ACTA2 mRNA Ursolic Acid affects the expression of ACTA2 protein |
CTD |
PMID:35786050 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization decreases response to substance |
ISO |
Ursolic Acid results in increased localization of AIFM1 protein AIFM1 mutant form results in decreased susceptibility to Ursolic Acid |
CTD |
PMID:20630652 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Ursolic Acid results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:19344998 PMID:24802810 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [APP protein modified form results in decreased expression of RPT-3 protein]; Ursolic Acid inhibits the reaction [APP protein modified form results in increased susceptibility to Serotonin] |
CTD |
PMID:34902447 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of ARG1 mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases activity |
ISO |
Ursolic Acid results in increased activity of BAK1 protein |
CTD |
PMID:20630652 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Ursolic Acid results in increased expression of BAX protein Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of BAX protein] |
CTD |
PMID:16012738 PMID:24051192 PMID:36587836 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions increases phosphorylation |
ISO |
Ursolic Acid results in decreased expression of BCL2 mRNA; Ursolic Acid results in decreased expression of BCL2 protein [Ursolic Acid results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of BCL2 protein] |
CTD |
PMID:16012738 PMID:24802810 PMID:28868958 PMID:36587836 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
[Ursolic Acid results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BECN1 protein]; Ursolic Acid inhibits the reaction [BCL2 protein binds to BECN1 protein] |
CTD |
PMID:24802810 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
ISO EXP |
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Ursolic Acid results in increased cleavage of and results in increased activity of CASP3 protein]; Ursolic Acid results in increased cleavage of and results in increased activity of CASP3 protein Ursolic Acid results in increased activity of CASP3 protein Ursolic Acid results in increased expression of CASP3 protein Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:16012738 PMID:19329757 PMID:20005942 PMID:24051192 PMID:34569348 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Ursolic Acid results in increased activity of CASP7 protein |
CTD |
PMID:19329757 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Ursolic Acid results in increased activity of CASP8 protein |
CTD |
PMID:20005942 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of CASP9 protein] |
CTD |
PMID:34569348 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity |
ISO |
Ursolic Acid results in increased activity of CAT protein |
CTD |
PMID:24051192 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Ursolic Acid results in decreased expression of CCND1 mRNA; Ursolic Acid results in decreased expression of CCND1 protein [Ursolic Acid co-treated with 2-Methoxyestradiol] results in decreased expression of CCND1 mRNA |
CTD |
PMID:24566423 PMID:24802810 PMID:38044485 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CCND3 protein |
CTD |
PMID:24802810 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CCNE1 protein |
CTD |
PMID:24802810 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CDK4 protein |
CTD |
PMID:24802810 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Ursolic Acid results in increased expression of CDKN1A protein |
CTD |
PMID:24802810 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Ursolic Acid results in increased expression of CDKN1B protein |
CTD |
PMID:24802810 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases expression |
ISO |
[Ursolic Acid co-treated with 2-Methoxyestradiol] results in decreased expression of CTNNB1 mRNA; Ursolic Acid results in increased phosphorylation of and results in increased degradation of CTNNB1 protein Ursolic Acid results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:24566423 PMID:38044485 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases secretion |
ISO |
Ursolic Acid results in decreased secretion of CXCL12 protein |
CTD |
PMID:35786050 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CXCL2 mRNA] |
CTD |
PMID:26513295 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of CXCR4 mRNA; Ursolic Acid results in decreased expression of CXCR4 protein |
CTD |
PMID:35786050 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Ursolic Acid affects the localization of CYCS protein |
CTD |
PMID:16012738 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions decreases activity |
ISO |
Ursolic Acid inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] Ursolic Acid results in decreased activity of CYP2C19 protein |
CTD |
PMID:15043991 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; Acetylcysteine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A promotes the reaction [bardoxolone methyl results in increased expression of DDIT3 protein]]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of DDIT3 protein] Ursolic Acid inhibits the reaction [Paclitaxel results in increased expression of DDIT3 mRNA] |
CTD |
PMID:24802810 PMID:36587836 PMID:38437959 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Choline results in increased expression of EDN1 protein] |
CTD |
PMID:27567547 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR]] |
CTD |
PMID:26100520 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Ursolic Acid results in increased phosphorylation of EIF2AK3 protein EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased expression of DDIT3 protein]; EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; Ursolic Acid inhibits the reaction [HSPA5 protein binds to EIF2AK3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
EIF2AK3 mutant form inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased phosphorylation of EIF2S1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of EIF4EBP1 protein |
CTD |
PMID:24802810 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases activity |
ISO |
Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of ERN1 protein] Ursolic Acid results in increased activity of ERN1 protein |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fap |
fibroblast activation protein, alpha |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of FAP mRNA; Ursolic Acid results in decreased expression of FAP protein |
CTD |
PMID:35786050 |
|
NCBI chr 3:47,138,823...47,207,671
Ensembl chr 3:47,138,813...47,225,545
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR3 mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fcgr2b |
Fc gamma receptor 2B |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR2B mRNA] |
CTD |
PMID:37019307 |
|
NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Choline results in increased activity of GPT protein] |
CTD |
PMID:27567547 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO |
Ursolic Acid results in increased expression of HSPA5 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; Acetylcysteine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in increased expression of HSPA5 protein]; Ursolic Acid inhibits the reaction [HSPA5 protein binds to EIF2AK3 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in increased expression of HSPA5 protein] |
CTD |
PMID:24802810 PMID:36587836 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of ICAM1 mRNA; Ursolic Acid results in decreased expression of ICAM1 protein |
CTD |
PMID:20005942 PMID:21539908 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of CHIL3 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]]; [Ursolic Acid co-treated with IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MRC1 mRNA; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of ARG1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of CHIL3 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR2B mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of FCGR3 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein] |
CTD |
PMID:37019307 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:34569348 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
[Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA] Ursolic Acid results in decreased expression of IL6 protein Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of IL6 protein] |
CTD |
PMID:20869956 PMID:23835587 PMID:34569348 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUN]] |
CTD |
PMID:23835587 PMID:26100520 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lep |
leptin |
increases expression |
ISO |
Ursolic Acid results in increased expression of LEP protein |
CTD |
PMID:20869956 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of LONP1 protein] |
CTD |
PMID:36587836 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:27274199 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:27274199 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK8 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:27274199 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK9 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:27274199 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mir140 |
microRNA 140 |
increases expression |
ISO |
Ursolic Acid results in increased expression of MIR140 mRNA |
CTD |
PMID:38044485 |
|
NCBI chr19:35,465,577...35,465,675
Ensembl chr19:35,465,577...35,465,675
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO EXP |
[Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein; Ursolic Acid results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP2 protein 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein] Ursolic Acid results in decreased expression of MMP2 mRNA 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP2 protein] |
CTD |
PMID:21539908 PMID:27274199 PMID:36191607 PMID:37019307 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO EXP |
Ursolic Acid results in decreased expression of MMP9 mRNA 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MMP9 protein] [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of and results in decreased expression of MMP9 protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein; Ursolic Acid results in decreased secretion of and results in decreased activity of and results in decreased expression of MMP9 protein 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein] |
CTD |
PMID:21539908 PMID:27274199 PMID:36191607 PMID:37019307 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
[Ursolic Acid co-treated with IFNG protein co-treated with Lipopolysaccharides] results in increased expression of MRC1 mRNA |
CTD |
PMID:37019307 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions decreases phosphorylation |
ISO |
ursodoxicoltaurine inhibits the reaction [Ursolic Acid results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:24802810 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NFKB1 protein] |
CTD |
PMID:23835587 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Ursolic Acid analog results in decreased phosphorylation of and results in increased expression of NFKBIA protein |
CTD |
PMID:26134000 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of NOS2 protein |
CTD |
PMID:24051192 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Ursolic Acid inhibits the reaction [Choline results in increased expression of NOS3 protein] |
CTD |
PMID:27567547 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Ursolic Acid results in increased cleavage of PARP1 protein |
CTD |
PMID:16012738 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases secretion multiple interactions |
ISO |
Ursolic Acid results in decreased secretion of PLAU protein [Ursolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in decreased secretion of PLAU protein; [Ursolic Acid co-treated with Oleanolic Acid] results in decreased secretion of PLAU protein |
CTD |
PMID:36191607 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
decreases expression multiple interactions |
ISO |
Ursolic Acid results in decreased expression of PLAUR protein [Ursolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid co-treated with Irinotecan] results in increased secretion of and results in decreased expression of PLAUR protein; [Ursolic Acid co-treated with Oleanolic Acid] results in increased secretion of and results in decreased expression of PLAUR protein |
CTD |
PMID:36191607 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of PPARG protein] 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of PPARG protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of PPARG protein] |
CTD |
PMID:27274199 PMID:37019307 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2]] |
CTD |
PMID:23835587 PMID:26100520 PMID:26513295 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
decreases activity |
ISO |
Ursolic Acid results in decreased activity of PTPN1 protein |
CTD |
PMID:27085377 PMID:29175190 PMID:30160205 PMID:36933777 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
Ursolic Acid analog results in decreased expression of RELA mRNA; Ursolic Acid analog results in decreased expression of RELA protein |
CTD |
PMID:26134000 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of RPS6KB1 protein |
CTD |
PMID:24802810 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
increases expression multiple interactions |
ISO |
Ursolic Acid results in increased expression of SIGMAR1 protein Ursolic Acid inhibits the reaction [bardoxolone methyl results in decreased expression of SIGMAR1 protein]; Ursolic Acid inhibits the reaction [ochratoxin A results in decreased expression of SIGMAR1 protein] |
CTD |
PMID:36587836 |
|
NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SRC]] |
CTD |
PMID:26100520 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Resveratrol promotes the reaction [Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]]; Ursolic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]; Ursolic Acid promotes the reaction [Resveratrol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAT3]] |
CTD |
PMID:26100520 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of TGFB1 protein |
CTD |
PMID:21539908 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression multiple interactions |
ISO |
Ursolic Acid results in decreased expression of TGFB3 mRNA; Ursolic Acid results in decreased expression of TGFB3 protein [Ursolic Acid co-treated with 2-Methoxyestradiol] results in decreased expression of TGFB3 mRNA |
CTD |
PMID:38044485 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TIMP1 protein]]; Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TIMP1 protein] 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]]; 2-chloro-5-nitrobenzanilide promotes the reaction [Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein]]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 mRNA]; Ursolic Acid inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in decreased expression of TIMP1 protein] |
CTD |
PMID:27274199 PMID:37019307 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
Ursolic Acid results in decreased expression of TNF protein Ursolic Acid inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:24051192 PMID:34569348 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Ursolic Acid results in decreased activity of TOP1 protein |
CTD |
PMID:10860928 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases activity |
ISO |
Ursolic Acid results in decreased activity of TOP2A protein |
CTD |
PMID:10860928 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of VEGFA protein |
CTD |
PMID:24051192 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
Ursolic Acid results in decreased expression of VIM mRNA; Ursolic Acid results in decreased expression of VIM protein |
CTD |
PMID:35786050 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|